-
Je něco špatně v tomto záznamu ?
De-Intensification from Basal-Bolus Insulin Therapy to Liraglutide in Type 2 Diabetes: Predictive Value of Mean Glycaemia during Fasting Test
B. Pavlikova, M. Breburdova, M. Krcma, M. Kriz, J. Kasparek, Z. Rusavy
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
GA UK 442220
Charles University
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
PubMed
38792590
DOI
10.3390/life14050568
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Successful conversion from insulin therapy to glucagon-like peptide 1 receptor agonist (GLP-1RA) with basal insulin in well-controlled patients has already been demonstrated. However, the data concerning individuals with poor glycaemic control are scarce. The aim of this work was to assess the success rate of insulin therapy to liraglutide transition in poorly controlled diabetes in a real-world clinical setting and to define predictors of success. We are the first to present the method of a fasting test as a way to identify the patients at higher risk of failure after treatment de-intensification. METHODS: The retrospective observational study analyzed data of 62 poorly controlled obese diabetic patients on high-dose insulin therapy, who were subjected to a 72 h fasting test during hospitalization and subsequently switched to liraglutide ± basal insulin therapy. During the fasting, all antidiabetic treatment was discontinued. Patients were classified as responders if they remained on GLP-1RA treatment after 12 months. Non-responders restarted the basal-bolus insulin (BBI) regimen. Development of glycated hemoglobin (HbA1c) and body weight in both groups, alongside with parameters associated with the higher risk of return to the BBI regimen, were analyzed. RESULTS: A total of 71% of patients were switched successfully (=responders). Responders had more significant improvement in HbA1c (-6.4 ± 19.7 vs. -3.4 ± 22.9 mmol/mol) and weight loss (-4.6 ± 7.1 vs. -2.5 ± 4.0). Statistically significant difference between groups was found in initial HbA1c (75.6 ± 17.9 vs. 90.5 ± 23.6; p = 0.04), total daily dose of insulin (67.6 ± 36.4 vs. 90.8 ± 32.4; p = 0.02), and mean glycaemia during the fasting test (6.9 ± 1.7 vs. 8.6 ± 2.2 mmol/L; p < 0.01). CONCLUSIONS: This study confirms that therapy de-intensification in poorly controlled patients with a BBI regimen is possible. Higher baseline HbA1c, total daily insulin dose, and mean glucose during fasting test are negative predictive factors of successful therapy de-escalation.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24012906
- 003
- CZ-PrNML
- 005
- 20240726151440.0
- 007
- ta
- 008
- 240723s2024 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/life14050568 $2 doi
- 035 __
- $a (PubMed)38792590
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Pavlikova, Barbora $u First Department of Internal Medicine, University Hospital Pilsen, Charles University, Faculty of Medicine in Pilsen, 323 00 Pilsen, Czech Republic $1 https://orcid.org/0000000299171074
- 245 10
- $a De-Intensification from Basal-Bolus Insulin Therapy to Liraglutide in Type 2 Diabetes: Predictive Value of Mean Glycaemia during Fasting Test / $c B. Pavlikova, M. Breburdova, M. Krcma, M. Kriz, J. Kasparek, Z. Rusavy
- 520 9_
- $a BACKGROUND: Successful conversion from insulin therapy to glucagon-like peptide 1 receptor agonist (GLP-1RA) with basal insulin in well-controlled patients has already been demonstrated. However, the data concerning individuals with poor glycaemic control are scarce. The aim of this work was to assess the success rate of insulin therapy to liraglutide transition in poorly controlled diabetes in a real-world clinical setting and to define predictors of success. We are the first to present the method of a fasting test as a way to identify the patients at higher risk of failure after treatment de-intensification. METHODS: The retrospective observational study analyzed data of 62 poorly controlled obese diabetic patients on high-dose insulin therapy, who were subjected to a 72 h fasting test during hospitalization and subsequently switched to liraglutide ± basal insulin therapy. During the fasting, all antidiabetic treatment was discontinued. Patients were classified as responders if they remained on GLP-1RA treatment after 12 months. Non-responders restarted the basal-bolus insulin (BBI) regimen. Development of glycated hemoglobin (HbA1c) and body weight in both groups, alongside with parameters associated with the higher risk of return to the BBI regimen, were analyzed. RESULTS: A total of 71% of patients were switched successfully (=responders). Responders had more significant improvement in HbA1c (-6.4 ± 19.7 vs. -3.4 ± 22.9 mmol/mol) and weight loss (-4.6 ± 7.1 vs. -2.5 ± 4.0). Statistically significant difference between groups was found in initial HbA1c (75.6 ± 17.9 vs. 90.5 ± 23.6; p = 0.04), total daily dose of insulin (67.6 ± 36.4 vs. 90.8 ± 32.4; p = 0.02), and mean glycaemia during the fasting test (6.9 ± 1.7 vs. 8.6 ± 2.2 mmol/L; p < 0.01). CONCLUSIONS: This study confirms that therapy de-intensification in poorly controlled patients with a BBI regimen is possible. Higher baseline HbA1c, total daily insulin dose, and mean glucose during fasting test are negative predictive factors of successful therapy de-escalation.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Breburdova, Martina $u First Department of Internal Medicine, University Hospital Pilsen, Charles University, Faculty of Medicine in Pilsen, 323 00 Pilsen, Czech Republic
- 700 1_
- $a Krcma, Michal $u First Department of Internal Medicine, University Hospital Pilsen, Charles University, Faculty of Medicine in Pilsen, 323 00 Pilsen, Czech Republic $1 https://orcid.org/0000000215642503 $7 mzk2007390690
- 700 1_
- $a Kriz, Miroslav $u First Department of Internal Medicine, University Hospital Pilsen, Charles University, Faculty of Medicine in Pilsen, 323 00 Pilsen, Czech Republic
- 700 1_
- $a Kasparek, Jan $u First Department of Internal Medicine, University Hospital Pilsen, Charles University, Faculty of Medicine in Pilsen, 323 00 Pilsen, Czech Republic
- 700 1_
- $a Rusavy, Zdenek $u First Department of Internal Medicine, University Hospital Pilsen, Charles University, Faculty of Medicine in Pilsen, 323 00 Pilsen, Czech Republic
- 773 0_
- $w MED00186366 $t Life $x 2075-1729 $g Roč. 14, č. 5 (2024)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38792590 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240723 $b ABA008
- 991 __
- $a 20240726151432 $b ABA008
- 999 __
- $a ok $b bmc $g 2125517 $s 1224769
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 14 $c 5 $e 20240428 $i 2075-1729 $m Life $n Life (Basel) $x MED00186366
- GRA __
- $a GA UK 442220 $p Charles University
- LZP __
- $a Pubmed-20240723